[低分子医薬品] Lonzaが 高薬理活性原薬 (HPAPI) の受託製造開発設備を増強

・Lonza will develop new facilities at its Visp, CH site in order to meet customer needs for highly potent API (HPAPI), in particular for the oncology market.

・Two 4m³-scale, multi-purpose production lines, expected online by July 2020.

・New capacity completes Lonza’s range of HPAPI capabilities from development to commercial scale manufacturing, including formulation and delivery.

(リンクより全文をご覧いただけます/英語)

• リリース元を見る